NCT02073474 - An Observational Post-Marketing Safety Registry of Sativex® | Biotech Hunter

Enrollment

978

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Multiple SclerosisDiabetesCancerNeuropathic Pain

Interventions

DRUG

Sativex®

Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.